ZYME

26.6200.89%
MH

Mark Hollywood

Executive VP & COO

Mr. Mark Hollywood serves as an Executive VP and Head of Technical & Manufacturing Operations at Zymeworks Inc. since January 2026. He served as Senior Vice President of Technical & Manufacturing Operations at Zymeworks Inc., since March 2019. He served as Director of Quality Assurance & Quality Control of Cellcyte Genetics Corporation since May 2007. Mr. Hollywood experience in the biopharmaceutical industry, most recently as Vice President and Head of ZymoGenetics, Inc. (a Bristol-Myers Squibb company), where he led outsourced manufacturing and supply chain operations and was responsible for building a multi-host biological drug substance manufacturing facility. Mr. Hollywood was responsible for leading CellCyte's Quality Operations, including the oversight of QA/QC for preclinical, clinical and manufacturing activities, as well as regulatory compliance. He had been involved in a broad range of activities associated with the development and commercialization of novel recombinant protein therapeutics, cellular immunotherapies and human plasma derived products. He served in positions of increasing responsibility throughout his career with major biotechnology companies, including Zymogenetics, Dendreon, Amgen and Centeon/Aventis. He served as Associate Director of Quality for Zymogenetics, overseeing its GxP Quality Operations. He provided quality oversight for Zymogenetic's preclinical, clinical, manufacturing and validation functions. He served as Associate Director of Quality Compliance of Dendreon, where he focused on ensuring compliance for their active cellular immunotherapy program. Mr. Hollywood served at Amgen where, he managed regulatory compliance activities for its epoetin alfa products, Epogen(R) and Aranesp(R), at their Longmont, CO site. He managed successful international regulatory inspections performed by FDA's Center for Biologics Evaluation and Research (CBER), the European Medicines Evaluation Agency (EMEA) Inspections Section and Health Canada's Biologics and Genetic Therapies Directorate (BGTD). He was also responsible for managing site specific regulatory activities associated with the licensure of these products. He joined Amgen to start-up the B-7 manufacturing facility for the clinical supply and commercialization of Aranesp(R) in Thousand Oaks, CA. He started his career at Centeon/Aventis where, he served as Process Development Scientist and Supervisor for its commercial manufacturing operations. Mr. Hollywood received a Bachelor of Science degree in Microbiology and Biochemistry from Western Illinois University.

Positions